Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07366086 · ClinicalTrials.gov registry record · Phase 3
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
A Phase 3 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT07366086: Recruiting Phase 3 study, sponsored by Amgen.
NCT07366086 is a Phase 3 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 71 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07366086, a Phase 3 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DIETARY_SUPPLEMENT Calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2028-04-19 |
| Phase | Phase 3 |
What NCT07366086 shows while recruiting
NCT07366086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Vitamin D is the first listed.
NCT07366086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07366086 about?
NCT07366086 is a clinical study titled "Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta". The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational...
What is the current status of trial NCT07366086?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2026-03-18. Estimated completion is 2028-04-19.
What interventions are being tested in trial NCT07366086?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Calcium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07366086?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07366086's enrollment target sits among peer trials
71 1784th of 2000 higher than 216 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI